This is a routine operational milestone for a pre-revenue biotech. Monitor for subsequent IND filing and initiation of clinical trials, which would be the next material catalyst. The $2M market cap and going-concern risk (noted in forward-looking statements) suggest capital needs remain acute.
Price Chart
Executive Summary
Genprex announced a development and manufacturing agreement with a U.S.-based CDMO to scale up production of its diabetes gene therapy candidate from research-grade to clinical/commercial-ready cGMP output. The collaboration supports IND-enabling preclinical studies and future clinical trials for the AAV-based therapy targeting Type 1 and Type 2 diabetes. No financial terms or revenue figures were disclosed, making this an early-stage operational update with no near-term catalyst.
Key Facts
- Entered into a development and manufacturing agreement with a leading U.S. CDMO for diabetes gene therapy program
- CDMO will manufacture AAV-based therapy in cGMP-compliant facility for IND-enabling studies and future trials
- Manufacturing roadmap includes process optimization, scale-up, analytical qualification, and GMP compliance
- Therapy delivers Pdx1 and MafA genes via AAV vector; preclinical data in mouse and NHP models showed restored glucose control and reduced insulin requirements
- Also exploring non-viral lipid nanoparticle delivery for potential re-dosing
Financial Impact
No financial terms disclosed; agreement is a manufacturing services contract with undisclosed value
Risk Factors
- Pre-revenue stage with no approved products or revenue
- Going-concern risk and need for additional capital to fund operations
- Early-stage preclinical program with no clinical data yet
- Manufacturing scale-up may face technical or regulatory delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-028250 |
| Document: 0001437749-26-028250-index-headers.html | 0001437749-26-028250 |
| Document: 0001437749-26-028250-index.html | 0001437749-26-028250 |
| Document: 0001437749-26-028250.txt | 0001437749-26-028250 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.05 | awaiting T+60 | — | $1.81 (−11.71%) |
Aug 18, 2026 9w ago | 8-K | $3.95 | awaiting T+60 | — | $1.81 (−54.18%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.81 (−61.89%) |
Jul 14, 2026 14w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.81 (−290.76%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.81 (+229.03%) |
May 26, 2026 21w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.81 (−89.34%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.81 (−90.44%) |
Apr 28, 2026 25w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.81 (−91.11%) |
Apr 21, 2026 26w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.81 (−92.45%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.81 (−9.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers